NCT06709326
APACA-Apheresis/acoustophoresis and Molecular Characterization of Prostate Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Identify circulating tumor cells (CTC) for molecular characterization
Timeframe: At inclusion in the study and after 4 weeks of treatment.
Differentiated gene expression in CTCs before and after treatment start
Timeframe: At inclusion in the study and after 4 weeks of treatment.
Phenotypical changes of immune cells due to anti-androgen treatment
Timeframe: At inclusion in the study, after 4 weeks of treatment, after 3, 6 and 12 months of treatment.
Secondary (1)
Progression free survival
Arms and interventions
Primary metastatic prostate cancerExperimental
Men who have not previously received treatment for prostate cancer.
PSA relapseExperimental
Men with PSA recurrance after surgery.
Healthy research subjectsOther
Control group to distinguish tumor-specific changes from normal signals.
Diagnostic tests: Apheresis, Anti androgen therapy
Other: Androgen deprivation therapy
Sites
1 site in 1 country
- Department of surgical and perioperative sciences, Umeå universityUmeå, Norrlands University Hospital, Sweden